FIELD: biotechnologies.
SUBSTANCE: invention relates to the biotechnology. Described are antisense oligonucleotides consisting of 10–28 nucleotides, and at least two of 10–28 nucleotides represent LNA, and the antisense oligonucleotide is complementary to a region of the gene coding TGF-RII, or a region of mRNA encoding TGF-RII. What is described is a pharmaceutical composition containing such antisense oligonucleotides.
EFFECT: said nucleotides are used for preventing and treating neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
14 cl, 32 dwg, 85 tbl, 640 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISENSE OLIGONUCLEOTIDES TO ALPHA-SYNUCLEIN AND APPLICATIONS THEREOF | 2019 |
|
RU2773197C2 |
| AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDES AND COMPOSITIONS CONTAINING THEM FOR THE PREVENTION AND TREATMENT OF FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES | 2019 |
|
RU2795179C2 |
| DOUBLE-CHAINED OLIGONUCLEOTIDE SPECIFIC TO CTGF GENE AND COMPOSITION CONTAINING IT FOR PREVENTION AND TREATMENT OF FIBROUS DISEASES AND DISEASES ASSOCIATED WITH RESPIRATORY SYSTEM | 2020 |
|
RU2807108C1 |
| TREATMENT OF TUMORS OF DISEASES RELATED TO THE GENOM-SUPPRESSOR BY THERAPY OF NATURAL TRANSCRIPT INHIBITION IN ANTI-SIGNIFICANT ORIENTATION REGARDING THIS GENE | 2009 |
|
RU2746478C2 |
| OLIGONUCLEOTIDES FOR LOWERING PD-L1 EXPRESSION | 2017 |
|
RU2747822C2 |
| ANTISENSE OLIGONUCLEOTIDES | 2022 |
|
RU2840656C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2747734C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2777570C2 |
| OLIGONUCLEOTIDES FOR REDUCING EXPRESSION OF PD-L1 | 2017 |
|
RU2835926C1 |
| COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASE ASSOCIATED WITH OBESITY, CONTAINING AMPHIREGULIN-SPECIFIC DOUBLE-CHAIN OLIGONUCLEOTIDE STRUCTURE | 2021 |
|
RU2810514C1 |
